Antibody-guided radiation therapy of cancer.
Radioimmunotherapy (RIT) using radiolabeled monoclonal antibodies (MAbs) directed against tumor-associated antigens has evolved from an appealing concept to one of the standard treatment options for patients with non-Hodgkin's lymphoma (NHL). Inefficient localization of radiolabeled MAbs to nonhematological cancers due to various tumor-related factors, however, has refrained RIT from outgrowing the experimental stage in solid tumors. Still, small volume or minimal residual disease has been recognized as a potentially suitable target for radiolabeled antibodies. Several strategies are being explored aimed at improving the targeting of radiolabeled MAbs to solid tumors thus improving their therapeutic efficacy. In this review, a historical overview of the application of RIT is given and various aspects of the application of radiolabeled MAbs as anti-cancer agents are discussed. Finally, the clinical results of RIT of NHL, colorectal cancer, ovarian cancer, breast cancer, and renal cell cancer are reviewed.
Koppe
Manuel J
MJ
Department of Surgery, Radboud University Nijmegen Medical Center, The Netherlands. m.koppe@chir.umcn.nl
Postema
Ernst J
EJ
Aarts
Frits
F
Oyen
Wim J G
WJ
Bleichrodt
Robert P
RP
Boerman
Otto C
OC
D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D000951:Antigens, Neoplasm / Q000276:immunology*; D006801:Humans; D000922:Immunotoxins / Q000276:immunology / Q000627:therapeutic use*; D009369:Neoplasms / Q000276:immunology* / Q000532:radiotherapy*; D016499:Radioimmunotherapy / Q000379:methods*; D011868:Radioisotopes / Q000008:administration & dosage / Q000009:adverse effects; D011874:Radiometry
D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D000922:Immunotoxins; D011868:Radioisotopes